Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis

Antiplatelet therapy, including aspirin, has been used for the secondary prevention of non-cardioembolic ischemic stroke [1]. Because patients who have a higher risk of recurrent stroke need antiplatelet agents with higher efficacy than aspirin, dual antiplatelet therapy (DAPT) has been used in cases requiring higher efficacy, such as the acute stage of stroke or high-risk patients [2]. However, DAPT is notably associated with an increased risk of bleeding like a two-edged sword [3]. Aspirin plus clopidogrel is recommended for a few weeks after acute ischemic stroke, preventing bleeding risk from not exceeding the power of preventing recurrent stroke [1].
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Source Type: research